Novartis eyes $1B Lutathera acceleration with trial win in newly diagnosed neuroendocrine tumors

Novartis hopes new data will open a $1 billion market opportunity for its radioligand therapy, Lutathera, as a first-line treatment.

Friday, the company’s ambition received a boost from the phase 3 readout of the NETTER-2 trial. In the study, Lutathera, plus long-acting release (LAR) octreotide, slashed the risk of disease progression or death by 72% versus high-dose octreotide LAR alone in newly diagnosed patients with grade 2 or 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are somatostatin receptor (SSTR)-positive.